64. Thrombotic thrombocytopenic purpura Clinical trials / Disease details

Clinical trials : 92 / Drugs : 85 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 76

diseases per page:

Showing 1 to 10 of 92 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05714969 (ClinicalTrials.gov)	March 21, 2023	24/1/2023	A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immu ...	A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13 ...	Thrombotic Thrombocytopenic Purpura (TTP)	Biological: TAK-755	Takeda	Takeda Development Center Americas, Inc.	Not yet recruiting	18 Years	N/A	All	40	Phase 2	NULL
2	EUCTR2022-001940-36-ES (EUCTR)	13/02/2023	22/12/2022	A Phase 2b study of TAK-755 (rADAMTS13) with minimal to no PEX in the treatment of patients with iTT ...	A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13 ...	immune-mediated thrombotic thrombocytopenic purpura(iTTP) MedDRA version: 20.0;Level: SOC;Classifica ...	Product Name: Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 ( ...	Takeda Development Center Americas, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Argentina;United States;United Kingdom;Switzerland;Spain;Greece;Canada;Austria;Poland;Italy;Israel;F ...
3	NCT05468320 (ClinicalTrials.gov)	November 21, 2022	18/7/2022	Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults W ...	An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and ...	Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab;Drug: Corticosteroids;Biological: anti-CD20 antibody	Sanofi	NULL	Recruiting	18 Years	80 Years	All	61	Phase 3	United States;Belgium;Czechia;France;Germany;Netherlands;Spain;United Kingdom
4	NCT05568147 (ClinicalTrials.gov)	October 1, 2022	25/9/2022	Aspirin for Prophylaxis of TTP	A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or A ...	Thrombotic Thrombocytopenic Purpura	Drug: Aspirin tablet;Drug: Placebo	The First Affiliated Hospital of Soochow University	NULL	Not yet recruiting	N/A	N/A	All	100	Phase 2/Phase 3	NULL
5	EUCTR2022-001177-31-DE (EUCTR)	15/09/2022	29/06/2022	Caplacizumab and immunosuppressive therapy without first line therapeutic plasma exchange in adults ...	An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and ...	Thrombotic Thrombocytopenic Purpura MedDRA version: 20.0;Level: PT;Classification code 10043648;Term ...	Trade Name: Cablivi ® Product Name: Cablivi ® Product Code: ALX0081 INN or Proposed INN: Caplacizumab Othe ...	Sanofi-Aventis Recherche & Développement	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	64	Phase 3	United States;Czechia;Greece;Spain;Austria;United Kingdom;Switzerland;Italy;France;Czech Republic;Ca ...
6	NCT05263193 (ClinicalTrials.gov)	June 8, 2022	22/2/2022	Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic ...	Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic ...	Immune-mediated Thrombocytopenic Purpura	Drug: Caplacizumab	Sanofi	NULL	Completed	N/A	18 Years	All	4		France
7	EUCTR2020-003348-10-IT (EUCTR)	15/02/2022	01/12/2021	A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic T ...	A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the sa ...	congenital Thrombotic thrombocytopenic purpura(TTP);Therapeutic area: Diseases [C] - Blood and lymph ...	Product Name: Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 Product ...	BAXALTA INNOVATIONS GMBH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	77	Phase 3	United States;Serbia;Portugal;Taiwan;Thailand;Spain;Ukraine;Israel;Russian Federation;Colombia;Switz ...
8	NCT05135442 (ClinicalTrials.gov)	December 1, 2021	6/11/2021	Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP	The Efficacy and Safety of Bortezomib as First-line Treatment for Acquired Thrombotic Thrombocytopen ...	Thrombotic Thrombocytopenic Purpura, Acquired	Drug: Bortezomib Injection	Peking Union Medical College Hospital	NULL	Not yet recruiting	18 Years	80 Years	All	30	Phase 4	China
9	EUCTR2020-003348-10-AT (EUCTR)	10/05/2021	28/01/2021	A continuation study to evaluate the prophylactic and on demand treatment of congenital Thrombotic T ...	A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the sa ...	congenital Thrombotic thrombocytopenic purpura(TTP);Therapeutic area: Diseases [C] - Blood and lymph ...	Product Name: Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13 Product ...	Baxalta Innovations GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	77	Phase 3	Serbia;Portugal;United States;Taiwan;Thailand;Spain;Ukraine;Russian Federation;Israel;Colombia;Italy ...
10	NCT04720261 (ClinicalTrials.gov)	May 1, 2021	12/1/2021	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTP	Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult Acqui ...	Thrombotic Thrombocytopenic Purpura, Acquired	Drug: Caplacizumab	University Hospital, Rouen	NULL	Not yet recruiting	18 Years	100 Years	All	125	Phase 2	NULL

First Previous1 2 3 4 5…10Next Last